Latest Content


Pharmaceutical Executive
0:49
The Rise of Oral GLP-1's
3 days ago
by
Nicholas Jacobus(+1 more)
Pharmaceutical Executive
0:41
The Impact of FDA's Approval of Papzimeos
4 days ago
by
Nicholas Jacobus(+1 more)
Pharmaceutical Executive
0:54
The Hidden Cost of Unmanaged Kidney Disease Complications
11 days ago
by
Nicholas Jacobus(+1 more)
How the DSCSA is Accelerating Digital Transformation
0:44
How the DSCSA is Accelerating Digital Transformation
19 days ago
by
Mike Hollan(+1 more)
Jay Bregman
0:48
The GLP-1 Shift to Mass Market
21 days ago
by
Mike Hollan(+1 more)
Ryan Conrad
0:57
FDA's Priority Voucher Review Program's Impact on Timelines
24 days ago
by
Mike Hollan(+1 more)
Why Platform Technologies are Essential for Biotech Investors
0:31
Why Platform Technologies are Essential for Biotech Investors
a month ago
by
Mike Hollan(+1 more)
Jaspal Singh
0:34
Why Upfront Molecular Testing is the Future of Systemic Therapy
a month ago
by
Mike Hollan(+1 more)
Craig Ackerman
0:59
Strategizing for Growth in 2025
a month ago
by
Mike Hollan(+1 more)
Pharmaceutical Executive
0:42
Balancing Innovation and Capital
a month ago
by
Nicholas Jacobus(+1 more)

Paul Hudson: A Mindset for Miracles

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Paul Hudson: A Mindset for Miracles

Pharmaceutical Executive: September 2025 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive September 2025 issue in an interactive PDF format.

Pharmaceutical Executive: September 2025 Issue (PDF)

Coaching Flag Football—And Guiding a Biotech Through Commercialization

Useful tips and parallels for staying in the game following a complete response letter.

Coaching Flag Football—And Guiding a Biotech Through Commercialization

From Lab to Market: Tracking Today’s Shifting Pathways for Biotech

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

From Lab to Market: Tracking Today’s Shifting Pathways for Biotech

Podcasts



All News

Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.